Broadcast Date: 
  • Time: 

To meet the demands of ever shorter cell line construction timelines, especially in manufacturing complex protein therapeutics such as bispecific antibodies, highly optimized cell and process technologies are required. In particular, it is critical to bring together technologies that synergize across the process, from stable transfection to clone screening, to generate the most productive cell lines.

In this GEN webinar, we will exemplify this approach by outlining how we have taken the GS piggyBac transposase technology for the creation of highly productive stable pools and clones and leveraged its potential by combining it with the Beacon platform for high-throughput single cell isolation and screening. Using data from in-house Lonza R&D and the latest customer case studies, we will demonstrate how the industry-leading CHOK1SV GS-KO cell line can be further leveraged to produce complex proteins using these two technology platforms.

A live Q&A followed the presentation, offering a chance to pose questions to our expert panelist.

Lonza Biologics logo

Sarah Turner
Sarah Turner
Senior Group Leader, R&D